Abstract: An extrusion-based additive manufacturing process including the step of selectively depositing a molten thermoplastic material (P) on a film or sheet made from or containing a polymer blend obtained by melt blending a mixture made from or containing: (A) 60% to 98.8% by weight of a polyolefin; (B) 0.1% to 30% by weight of a compatibilizer; (C) 0.05% to 20% by weight of an amino resin; and (D) 0% to 5% by weight of an additive, wherein the amounts of (A), (B), (C) and (D) are based on the total weight of (A)+(B)+(C)+(D).

Abstract: Disclosed is a method for closing the contacts of an electrical switching device during a switch-on process, wherein for a fixed first time period, the first time period and the first voltage being selected in such a way that the armature is not set into motion during the first time period, or the first voltage is applied to the coil until a certain current value is reached, the first time period being the time period until said certain current value is reached, and the first voltage being selected in such a way that the armature is not set into motion during the first time period, wherein a suitable second voltage is defined, the second voltage being greater than the first voltage and being applied to the coil during a second time period in order to move the armature from the open position into the closed position.

Abstract: The pharmaceutical preparations for treating side effects, such as hot flashes, prostate enlargement and gynecomastia, during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone (GnRHa therapy) contain an effective amount of a chemically modified derivative of 17&agr;-estradiol, a chemically modified derivative of 17&bgr;-estradiol and/or a chemical modified derivative of estriol. Pharmaceutical preparations containing estra 1,3,5(10)-triene-3,17&bgr;-diol-17-valerate as the effective ingredient are particularly preferred.

Abstract: The pharmaceutical preparations for treating side effects, such as hot flashes, prostate enlargement and gynecomastia, during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone (GnRHa therapy) contain an effective amount of a chemically modified derivative of 17&agr;-estradiol, a chemically modified derivative of 17&bgr;-estradiol and/or a chemical modified derivative of estriol. Pharmaceutical preparations containing 14&agr;, 15&agr;-methylene-1,3,5(10),8-tetraene-3,17&agr;-diol are particularly preferred.

Abstract: The pharmaceutical preparations for treating side effects, such as hot flashes, prostate enlargement and gynecomastia, during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone (GnRHa therapy) contain an effective amount of a chemically modified derivative of 17&agr;-estradiol, a chemically modified derivative of 17&bgr;-estradiol and/or a chemical modified derivative of estriol. Pharmaceutical preparations containing 14&agr;,15&agr;-methylene-1,3,5(10),8-tetraene-3,17&agr;-diol are particularly preferred.

Abstract: The pharmaceutical preparations for treating side effects, such as hot flashes, during and/or after treatment with analogs or antagonists of gonadotropin releasing hormone (GnRHa therapy) contain an effective amount of 17&agr;-estradiol, its chemically modified derivatives, chemically modified derivatives of 17&bgr;-estradiol or estriol.